Recent Updates — ELOX

The Board of Directors increased its size from five to six directors and appointed Geno J. Germano, a pharmaceutical industry veteran with extensive experience at Pfizer and Elucida Oncology, to fill the newly created vacancy. Mr. Germano brings deep knowledge in pipeline development and commercialization across multiple therapeutic areas. Concurrently, the company provided a corporate update regarding the appointment of T.R. Srinivas, M.D. as Senior Vice President and Chief Medical Officer, alongside the finalized design for its global Phase 2 clinical trial of exaluren in nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD). The EXPRESS trial will enroll approximately 60 adults randomized to receive exaluren or placebo for 52 weeks. First patient dosing is expected in the third quarter of 2027, with topline data anticipated in the first half of 2029. Eloxx Pharmaceuticals operates as a clinical-stage biotechnology company focused on developing therapies for rare genetic diseases.